Exact Sciences Hits New 1-Year High

Shares of the medical research company reach a new 52-week high.

Mar. 16, 2026 at 3:33pm

Got story updates? Submit your updates here. ›

Exact Sciences Corporation (NASDAQ:EXAS) reached a new 52-week high of $103.79 on Monday, with the stock closing at $103.77 on trading volume of 186,906 shares. The company, which is headquartered in Madison, Wisconsin, is known for its flagship product Cologuard, a non-invasive, stool-based DNA screening test for colorectal cancer.

Why it matters

Exact Sciences' stock price hitting a new 52-week high reflects growing investor confidence in the company's products and future prospects. As a leader in molecular diagnostics for cancer detection, Exact Sciences' performance is closely watched by industry analysts and investors.

The details

The stock's rise comes after several recent analyst reports. Wolfe Research cut its rating on Exact Sciences from "strong-buy" to "hold", while Mizuho reissued a "neutral" rating and raised its price target to $105. Overall, 21 analysts have a "hold" rating on the stock, and one has a "sell" rating, with an average price target of $92.13.

  • Exact Sciences stock hit a new 52-week high of $103.79 on Monday, March 16, 2026.

The players

Exact Sciences Corporation

A molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company's flagship product is Cologuard, a non-invasive, stool-based DNA screening test for colorectal cancer.

Got photos? Submit your photos here. ›

The takeaway

Exact Sciences' stock price hitting a new 52-week high reflects growing investor confidence in the company's cancer detection products and future growth potential. As a leader in the molecular diagnostics space, Exact Sciences' performance is closely watched by industry analysts and investors.